Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Barnes, B. Costall, R. Naylor, T. Williams, C. Wischik (1990)
Normal densities of 5-HT3 receptor recognition sites in Alzheimer's disease.Neuroreport, 1 3-4
IVERSEN IVERSEN (1984)
The Ferrier lecture, 1983. Amino acids and peptides: fast and slow chemical signals in the nervous systemProc. R. Soc., 221
G. Schiavi, S. Brunet, C. Rizzi, H. Ladinsky (1994)
Identification of serotonin 5-HT4 recognition sites in the porcine caudate nucleus by radioligand bindingNeuropharmacology, 33
B. Costall, R. Naylor (1993)
The pharmacology of the 5‐HT4 receptorInternational Clinical Psychopharmacology, 8
D. Flynn, D. Zabrowski, D. Becker, R. Nosal, C. Villamil, G. Gullikson, C. Moummi, D. Yang (1992)
SC-53116: the first selective agonist at the newly identified serotonin 5-HT4 receptor subtype.Journal of medicinal chemistry, 35 8
Yung‐chi Cheng, W. Prusoff (1973)
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.Biochemical pharmacology, 22 23
R. Katzman (1989)
Alzheimer's disease is a degenerative disorderNeurobiology of Aging, 10
(1995)
Serotonin facilitates long term potentiation in area CA 1 of rat hippocampus via 5 - HT 4 receptors
NORDBERG NORDBERG, LARSSON LARSSON, ADOLFSSON ADOLFSSON, SLATFUZOFT SLATFUZOFT, WINBLAD WINBLAD (1983)
Muscarinic receptor compensation in hippocampus of Alzheimer patientsJ. Neural Trans., 56
C. Waeber, M. Sebben, C. Grossman, F. Javoy‐Agid, J. Bockaert, A. Dumuis (1993)
[3H]-GR113808 labels 5-HT4 receptors in the human and guinea-pig brain.Neuroreport, 4 11
J. Barnes, Nicholas Barnes, B. Costall, James Ironside, R. Naylor (1989)
Identification and Characterisation of 5‐Hydroxytryptamine3 Recognition Sites in Human Brain TissueJournal of Neurochemistry, 53
(1994)
binding to 5-HT4 receptors in human neurodegenerative disorders
(1989)
The gastrointestinal prokinetic benzamide derivatives are agonists at the nonclassical 5 - HT ( 5 - HT 4 ) receptor coupled to adenylate cyclase in neurones
U. Frey, Yue Huang, E. Kandel (1993)
Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons.Science, 260 5114
J. Francis, W. Burnham (1992)
[3H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels.Molecular pharmacology, 42 6
J. Greenamyre, W. Maragos (1993)
Neurotransmitter receptors in Alzheimer disease.Cerebrovascular and brain metabolism reviews, 5 2
Characteriza - tion of the distribution of 5 - HT 4 receptors in human brain using [ 3 H ] GR 113808
A. Dumuis, R. Bouhelal, M. Sebben, R. Cory, J. Bockaert (1988)
A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system.Molecular pharmacology, 34 6
5 - HT 4 receptors : brain distribution and long term blockade of K + channels in cultured neurones
R. Eglen, K. Bley, D. Bonhaus, R. Clark, S. Hegde, L. Johnson, E. Leung, E. Wong (1993)
RS 23597‐190: a potent and selective 5‐HT4 receptor antagonistBritish Journal of Pharmacology, 110
R. Andrade, Y. Chaput (1991)
5-Hydroxytryptamine4-like receptors mediate the slow excitatory response to serotonin in the rat hippocampus.The Journal of pharmacology and experimental therapeutics, 257 3
(1993)
[ 1251 ] SB 207710 , a potent , selective radioligand for 5 - HT 4 receptors
L. Iversen (1984)
Amino acids and peptides: fast and slow chemical signals in the nervous system?, 221
C. Grossman, Gavin Kilpatrick, K. Bunce (1993)
Development of a radioligand binding assay for 5‐HT4 receptors in guinea‐pig and rat brainBritish Journal of Pharmacology, 109
T. Doménech, J. Beleta, A. Fernández, R. Gristwood, F. Sánchez, E. Tolosa, J. Palacios (1994)
Identification and characterization of serotonin 5-HT4 receptor binding sites in human brain: comparison with other mammalian species.Brain research. Molecular brain research, 21 1-2
KATZMAN KATZMAN (1989)
Alzheimer's disease is a neurodegenerative disorderNeurobiol. Ageing, 10
E. Monferini, P. Gaetani, R. Baena, E. Giraldo, M. Parenti, A. Zocchetti, C. Rizzi (1993)
Pharmacological characterization of the 5-hydroxytryptamine receptor coupled to adenylyl cyclase stimulation in human brain.Life sciences, 52 9
DOMENECH DOMENECH, BELETA BELETA, FERNANDEZ FERNANDEZ, GRISTWOOD GRISTWOOD, SANCHEZ SANCHEZ, TOLOSA TOLOSA, PALACIOS PALACIOS (1994)
Identification and characterization of serotonin 5‐HT 4 receptor binding sites in human brain: comparison with other mammalian speciesMol. Brain Res., 21
L. Jakeman, Z. To, R. Eglen, E. Wong, D. Bonhaus (1994)
Quantitative autoradiography of 5-HT4 receptors in brains of three species using two structurally distinct radioligands, [3H]GR113808 and [3H]BIMU-1Neuropharmacology, 33
REYNOLDS REYNOLDS, MASON MASON, MELDRUM MELDRUM, KECZER KECZER, PARNES PARNES, EGLEN EGLEN, WONG WONG (1994b)
( 3 H)GR 113808 binding to 5‐HT 4 receptors in human neurodegenerative disordersBr. J. Pharmacol., 112
WONG WONG, REYNOLDS REYNOLDS, BONHAUS BONHAUS, HSU HSU, EGLEN EGLEN (1995)
Characterization of ( 3 H)GR 113808 binding to 5‐HT 4 receptors in guinea‐pig and human brain. Proceedings, Third IUPHAR Satellite Meeting on Serotonin , Chicago, July 30th—August 3rdBehav. Brain Res.
J. Bockaert, H. Ansanay, Christian Waeber, M. Sebben, L. Fagni, A. Dumuis (2012)
5-HT4 ReceptorsCNS Drugs, 1
C. Gerald, N. Adham, H. Kao, M. Olsen, T. Laz, L. Schechter, J. Bard, P. Vaysse, P. Hartig, T. Branchek, R. Weinshank (1995)
The 5‐HT4 receptor: molecular cloning and pharmacological characterization of two splice variants.The EMBO Journal, 14
B. Tuladhar, B. Costal, R. Naylor (1996)
Pharmacological characterization of the 5‐hydroxytryptamine receptor mediating relaxation in the rat isolated ileumBritish Journal of Pharmacology, 119
A. Ford, D. Clarke (1993)
The 5‐HT4 ReceptorMedicinal Research Reviews, 13
K. Wardle, E. Ellis, G. Baxter, G. Kennett, L. Gaster, G. Sanger (1994)
The effects of SB 204070, a highly potent and selective 5‐HT4 receptor antagonist, on guinea‐pig distal colonBritish Journal of Pharmacology, 112
L. Forno (1992)
Neuropathologic Features of Parkinson's, Huntington's, and Alzheimer's Diseases aAnnals of the New York Academy of Sciences, 648
A. Ford, G. Baxter, R. Eglen, D. Clarke (1992)
5-Hydroxytryptamine stimulates cyclic AMP formation in the tunica muscularis mucosae of the rat oesophagus via 5-HT4 receptors.European journal of pharmacology, 211 1
(1994)
GR 125487: a 5-HT4 receptor antagonist with a long duration of action in vivo
Christian Waeber, M. Sebben, André Nieoullon, J. Bockaert, A. Dumuis (1994)
Regional distribution and ontogeny of 5-HT4 binding sites in rodent brainNeuropharmacology, 33
(1994)
Effect of two ben - zimidazolone derivatives : BIMU I and BIMU 8 on a model of hypoxia - induced amnesia in the mouse
G. Reynolds, S. Pearson, K. Heathfield (1990)
Dementia in Huntington's disease is associated with neurochemical deficits in the caudate nucleus, not the cerebral cortexNeuroscience Letters, 113
WARDLE WARDLE, ELLIS ELLIS, GASTER GASTER, KING KING, SANGER SANGER (1993)
SB 204070: a highly potent and selective 5‐HT 4 receptor antagonistBr. J. Pharmacol., 110
A. Cross, T. Crow, I. Ferrier, J. Johnson, S. Bloom, J. Corsellis (1984)
Serotonin Receptor Changes in Dementia of the Alzheimer TypeJournal of Neurochemistry, 43
Greenamyre Jt, Maragos Wf (1993)
Neurotransmitter receptors in Alzheimer disease., 5
R. Hayes, K. Miller, S. Akira, Y. Lin, C. Friedman, M. Kim (1993)
Pregnancy can be established in superovulated adult rats treated with progesterone and an aromatase inhibitor.Life sciences, 52 1
(1994)
Pro-cognitive effects of RS 66331
1 The distribution, pharmacology and effects of neurodegenerative diseases on 5‐HT4 receptors in human brain have been characterized in vitro. 2 The 5‐HT4 receptor in post mortem human brain tissue was specifically labelled with (3H)‐GR 113808. In human putamen, this ligand labelled a homogeneous population of sites, with an apparent affinity (‐log Kd) of 10.1 and a density (Bmax) of 5.73 fmol mg−1 tissue. The pharmacology of this site was characterized by use of a series of displacing ligands, and the following rank order of apparent affinities (with mean ± s.d. ‐log Ki values in parentheses) was generated: GR113808 (10.05 ± 0.04) > SDZ 205,557 (8.65 ± 0.08)> DAU 6285 (7.95 ± 0.04) > BIMU‐1 (7.81 ± 0.06) > DAU 6215 (7.42 ± 0.23) > tropisetron (7.39 ± 0.23)> 5‐HT (7.32 ± 1.00) > BIMU‐8 (7.25 ± 0.04) > (R)‐zacopride (5.82 ± 0.04). The Hill coefficients were not significantly different from unity, consistent with an interaction at a single site. A comparison of the affinities of these compounds with those obtained from guinea‐pig striatum indicated no evidence of species differences. 3 The regional distribution of 5‐HT4 receptors was assessed by determining the density of binding sites for (3H)‐GR 113808. The distribution were as follows (with mean ± s.d. Bmax values, fmol mg−1 tissue, in parentheses): caudate nucleus (8.7 ± 1.5), lateral pallidum (8.6 ± 5.5), putamen (5.7 ± 3.0), medial pallidum (3.8 ± 0.9), temporal cortex (2.6 ± 0.6), hippocampus (2.4 ± 0.8), amygdala (2.3 ± 1.1), frontal cortex (1.7 ± 0.5), cerebellar cortex (<1.0). In these studies, the affinities of GR 113808 were not significantly different. 4 The density of 5‐HT4 receptors selected from regions of post mortem brains of patients with Parkinson's disease, Huntington's disease and Alzheimer's disease were compared to age‐matched controls. In Parkinson's disease, there was no significant difference between control or patient values (mean ± s.d. Bmax values, fmol mg−1 tissue; putamen, control 4.74 ± 0.07, patient 5.86 ± 1.48; substantia nigra, control 4.21 ± 2.56, patient 5.57 ± 0.10). In Huntington's disease, there was a significant decrease in putamen (control 5.33 ± 1.08, patient 2.68 ± 1.08), while in Alzheimer's disease, there was a marked loss of receptors in hippocampus (control 2.34 ± 0.62, patient 0.78 ± 0.61), in frontal cortex (control, 1.76 ± 0.19, patient 1.30 ± 0.22). Receptor density in temporal cortex showed a decrease, but did not achieve statistical significance (control 2.06 ± 0.21, patient 1.44 ± 0.64). 5 These data suggest a heterogeneous distribution of 5‐HT4 receptors in human brain, with high to moderate densities in basal ganglia and limbic structures. These receptors may not be principally co‐localized on dopaminergic cell bodies or terminals, given the lack of change observed in Parkinson's disease. The loss of 5‐HT4 receptors in the putamen in Huntington's disease raises the possibility of their presence on intrinsic striatal GABAergic or cholinergic neurones. The marked loss of receptors in hippocampal and cortical regions in the brains from patients with Alzheimer's disease is consistent with a role for the 5‐HT4 receptor in cognitive processing.
British Journal of Pharmacology – Wiley
Published: Mar 1, 1995
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.